UK markets open in 7 hours 2 minutes
  • NIKKEI 225

    29,751.61
    +212.88 (+0.72%)
     
  • HANG SENG

    28,497.25
    +43.97 (+0.15%)
     
  • CRUDE OIL

    60.50
    +0.32 (+0.53%)
     
  • GOLD FUTURES

    1,747.20
    -0.40 (-0.02%)
     
  • DOW

    33,677.27
    -68.13 (-0.20%)
     
  • BTC-GBP

    46,217.73
    +2,343.60 (+5.34%)
     
  • CMC Crypto 200

    1,353.54
    +59.55 (+4.60%)
     
  • ^IXIC

    13,996.10
    +146.10 (+1.05%)
     
  • ^FTAS

    3,939.31
    +5.42 (+0.14%)
     

Puma Biotechnology to Present at the Barclays Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at the Barclays Global Healthcare Conference, which will be held virtually from March 9-11, 2021. Puma’s presentation will take place at 1:50 p.m. EST (10:50 a.m. PST) on Thursday, March 11, 2021.

A live webcast of the presentation will be available on the Company’s website at www.pumabiotechnology.com. The presentation will be archived on the website and available for 30 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005082/en/

Contacts

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com

David Schull or Maggie Beller, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com
maggie.beller@russopartnersllc.com